2Zou L, Zhang W, Ruan S. Modeling the transmission dynamics and control of hepatitis B virus in China [J]. J Theor Biol, 2010, 262(2): 330-338.
3Liaw Y F, Chu C M. Hepatitis B virus infection [J]. Lancet,2009, 373 (9663):582-592.
4Szmuness W, Stevens C E, Harley E J, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States [J]. N Engl J Med,1980,303 (15): 833-841.
5Salehi Hassan, Farajzadegan Ziba. Antibody titer in Iranian children 6 years after hepatitis B vaccine administration [J]. Vaccine, 2007, 25: 3511-3514.
6Kao J H, Chen D S. Global control of hepatitis B vires infection [J]. Lancet Infect Dis,2002,2(7):395-403.
7Nystrom J, Cardell K, Bjornsdottir T B, Fryden A, Hultgren C, Sallberg M. Improved cell mediated immune responses after successful re-vac- cination of non-responders to the hepatitis B virus surface antigen (HBsAg) vaccine using the combined hepatitis A and B vaccine [J]. Vaccine,2008,26(47)i5967-5972.
8Ni Y H, Chen D S. Hepatitis B vaccination in children: The Taiwan experience[J]. Pathologie Biologie, 2010, 58(4):296-300.
9Siegrist C A. Neonatal and early life vaccinology [J]. Vaccine,2001,19(25-26):3331-3346.
10Gjorup I E, Skinhoj P, Bottiger B, Plesner A M. Changing epidemiology of HBV infection in Danish children[J]. J Infect,2003,47(3):231-235.
